| Date Filed | Type | Description |
| 12/14/2022 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/28/2022 |
8-K
| Quarterly results |
| 09/30/2022 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 09/21/2022 |
8-K
| Investor presentation |
| 09/21/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 09/19/2022 |
SC 13G
| Hutchinson Thomas reports a 6.3% stake in Coeptis Therapeutics, Inc. |
| 09/16/2022 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 09/07/2022 |
253G2
| Form 253G2 - |
| 09/07/2022 |
8-K
| Quarterly results |
| 09/07/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/22/2022 |
8-K
| Quarterly results |
| 08/22/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/02/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/06/2022 |
8-K
| Quarterly results |
| 07/06/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/14/2022 |
RW
| Form RW - Registration Withdrawal Request: |
| 05/23/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/17/2022 |
8-K
| Quarterly results |
| 05/17/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/19/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 04/12/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 04/05/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/11/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/25/2022 |
8-K
| Quarterly results |
| 12/27/2021 |
8-K
| Quarterly results |
| 12/06/2021 |
253G1
| Form 253G1 - |
| 12/06/2021 |
QUALIF
| Form QUALIF - Notice of Qualification [Regulation A]: |
| 11/18/2021 |
4
| Mehalick David (CEO and President) has filed a Form 4 on Coeptis Therapeutics Inc.|
Txns:
| Sold 1,200,000 shares
@ $0 |
|
| 11/18/2021 |
1-A
| Form 1-A - Offering Statement [Regulation A]: |
| 11/15/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 10/12/2021 |
D/A
| Form D/A - Notice of Exempt Offering of Securities: [Amend] |
| 09/30/2021 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
|